{"download_date": ["ClinicalTrials.gov processed this data on May 09, 2023"], "link_text": ["Link to the current ClinicalTrials.gov record."], "url": ["https://clinicaltrials.gov/show/NCT00055614"], "org_study_id": ["BIDMC-E-010405FB"], "secondary_id": ["NEDH-E-010405FB"], "nct_id": ["NCT00055614"], "brief_title": ["Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer"], "official_title": ["Phase I Study of Oral Topotecan as Consolidation for Patients With Mullerian Origin Tumors (Ovary, Tube, Peritoneum)"], "lead_sponsor": [], "source": ["National Cancer Institute (NCI)"], "textblock": ["RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so\r\n      they stop growing or die.\r\n\r\n      PURPOSE: Phase I trial to study the effectiveness of topotecan in treating patients who have\r\n      advanced ovarian epithelial, fallopian tube, or primary peritoneal cancer.", "OBJECTIVES:\r\n\r\n        -  Determine the maximum tolerated dose and duration of prolonged topotecan as maintenance\r\n           in patients with advanced ovarian epithelial, fallopian tube, or primary peritoneal\r\n           cancer with complete clinical response after platinum-based chemotherapy.\r\n\r\n        -  Determine the safety of this regimen in these patients.\r\n\r\n      OUTLINE: This is a dose-escalation study.\r\n\r\n      Patients receive oral topotecan twice daily for 21 days. Treatment repeats every 28 days for\r\n      up to 6 months in the absence of unacceptable toxicity or disease progression.\r\n\r\n      Patients who tolerate course 1 may receive an escalated dose of topotecan for subsequent\r\n      courses. The maximum tolerated dose is defined as the dose tolerated by the majority of the\r\n      patients.\r\n\r\n      Patients are followed every 2 months for at least 6 months.\r\n\r\n      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study."], "overall_status": ["Completed"], "start_date": ["May 2002"], "type": ["Actual", "Anticipated", "Estimate", "Estimate"], "completion_date": ["October 2007"], "phase": ["Phase 1"], "study_type": ["Interventional"], "has_expanded_access": ["No"], "primary_purpose": ["Treatment"], "enrollment": [20.0], "condition": ["Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer"], "intervention_type": ["Drug", "Procedure"], "intervention_name": ["topotecan hydrochloride", "adjuvant therapy"], "criteria": [], "gender": ["Female"], "minimum_age": ["18 Years"], "maximum_age": [], "healthy_volunteers": ["No"], "last_name": ["Stephen A. Cannistra, MD"], "role": ["Study Chair"], "affiliation": ["Beth Israel Deaconess Medical Center"], "facility": [], "country": ["United States"], "verification_date": ["April 2007"], "study_first_submitted": ["March 6, 2003"], "study_first_submitted_qc": ["March 6, 2003"], "study_first_posted": ["March 7, 2003"], "last_update_submitted": ["June 25, 2013"], "last_update_submitted_qc": ["June 25, 2013"], "last_update_posted": ["June 26, 2013"], "keyword": ["stage III ovarian epithelial cancer", "stage IV ovarian epithelial cancer", "fallopian tube cancer", "primary peritoneal cavity cancer"], "mesh_term": ["Fallopian Tube Neoplasms", "Topotecan"]}